HASBROUCK HEIGHTS, N.J., Nov. 13, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2009. Nymox reported a net loss of $1,362,840, or $0.04 per share for the quarter and $3,587,251, or $0.12 per share for the nine months ending September 30, 2009, compared to $1,318,293, or $0.04 per share for the quarter and $3,714,188, or $0.13 per share for the nine months ending September 30, 2008. Net losses include stock compensation charges for the quarter of $322,808 in 2009 and $293,180 in 2008 and for the nine months of $881,344 in 2009 and $702,540 in 2008. The increase of the net loss for the quarter is mainly attributable to expenses relating to the launch of Phase 3 clinical trials for NX-1207. The decrease in net losses for the nine months period is attributable to reduced general and administrative expenditures compared to 2008. Product sales amounted to $71,904 for the quarter and $248,471 for the nine months ending September 30, 2009, compared to $82,171 and $306,849 for the same periods in 2008 due to a decrease in sales attributable to the current economic slowdown. The weighted average number of common shares outstanding for the nine months ended September 30, 2009 was 30,570,732 compared to 29,646,249 for the same period in 2008.
